|
|
|
|
|
by scirob
769 days ago
|
|
Biotech companies go public incredibly early compared to tech not sure if these guys have yet but it would have a huge impact on their stock price and likely hold of getting into conversation with a major pharma Co that can pay for the later trials |
|
A major PR push exposes them to as many investors as fast as possible both at the VC and public level. When the science is particularly solid, this process can happen fast and involve ridiculous amounts of money (i.e Sofosbuvir discovered 2007, first tested 2010, bought for $11 billion in 2011, approved 2013).